NEWS & EVENTS
Biomedica Partners with Marubeni Group as Exclusive Distributor to Accelerate AIXA® AI Bone Health Deployment in Japan
November 21,2025
![丸紅柏瑞醫[2]](/uploads/images/f9022159672d1621ed6645dd6368642d.jpeg "丸紅柏瑞醫[2]")
Major Milestone for Biomedica × Japan Market Expansion 🚀
I’m pleased to share an important milestone for Biomedica.
AIXA® Osteo — our AI-driven osteoporosis, sarcopenia, and fracture-risk assessment solution — has officially entered a strategic partnership with Marubeni Corporation through its AI-medical subsidiary Clairvo Technologies.
This collaboration marks a significant step forward in bringing Taiwan-developed medical AI into Japan’s highly regulated and clinically demanding market.
Early clinical validation conducted in Japanese medical centers showed strong performance even under Japan’s commonly used low-dose X-ray conditions, achieving:
• AUC 97.2%
• Sensitivity 95.7%
• Specificity 98.7%
• CCC = 0.994 vs DXA
These results further confirm AIXA’s readiness for real-world clinical deployment.
With aligned distribution channels, clinical pathways, and digital-health infrastructure, Biomedica and Marubeni will work together to accelerate broader adoption of AI-enabled bone health screening across Japan and Asia.
Source: Global Bio & Investment
https://lnkd.in/gTSxE-az
Proud of our team, our partners, and the shared vision to make clinically validated AI accessible, scalable, and impactful.
I’m pleased to share an important milestone for Biomedica.
AIXA® Osteo — our AI-driven osteoporosis, sarcopenia, and fracture-risk assessment solution — has officially entered a strategic partnership with Marubeni Corporation through its AI-medical subsidiary Clairvo Technologies.
This collaboration marks a significant step forward in bringing Taiwan-developed medical AI into Japan’s highly regulated and clinically demanding market.
Early clinical validation conducted in Japanese medical centers showed strong performance even under Japan’s commonly used low-dose X-ray conditions, achieving:
• AUC 97.2%
• Sensitivity 95.7%
• Specificity 98.7%
• CCC = 0.994 vs DXA
These results further confirm AIXA’s readiness for real-world clinical deployment.
With aligned distribution channels, clinical pathways, and digital-health infrastructure, Biomedica and Marubeni will work together to accelerate broader adoption of AI-enabled bone health screening across Japan and Asia.
Source: Global Bio & Investment
https://lnkd.in/gTSxE-az
Proud of our team, our partners, and the shared vision to make clinically validated AI accessible, scalable, and impactful.